Alamar Biosciences, Inc. Common Stock 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Alamar Biosciences reported total revenue of $29.4 million for Q2 2026, up 82% year over year from $16.2 million in Q2 2025.
- Consumables revenue was $15.5 million, increasing 147% year over year and accounting for 53% of total revenue.
- Instrument revenue grew 35% to $7.8 million, driven by new instrument placements.
- Service and other revenue was $6.2 million, up 49%, primarily from the Technology Access Program (TAP).
- Gross profit was $17.7 million with a gross margin of 60%, up from 53% in Q2 2025, driven by manufacturing efficiencies and a favorable product mix.
- Operating expenses totaled $31.2 million, up from $16.5 million, reflecting investments in personnel, infrastructure, and R&D.
- Net loss was $13.2 million compared to $7 million in Q2 2025.
- The installed base growth and consumable pull-through remain strong, with consumable pull-through above $400,000 per instrument annually.
- Geographically, 69% of revenue came from the Americas, 22% from EMEA, and 9% from APAC.
- Customer mix was 52% academic and research institutions, 42% biopharmaceutical companies, and 6% distributors.
- The company launched new products including the Neuro 220 panel, MDR tau assay, Immune 340 panel, and a dry blood spot extraction kit.
- Alamar expanded its strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures to profile over 140,000 plasma samples by 2027.
- The company is developing a clinical instrument (Argo Dx) and pursuing FDA marketing authorization as part of its diagnostic enablement strategy.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Alamar Biosciences second quarter 2026 financial results webcast call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Kari Mandeville, Vice President of Investor Relations and Corporate Communications.
Please proceed. Good afternoon, everyone, and thank you for joining us today to review Alamar Biosciences second quarter 2026 financial results.
Joining me on the call are Yuling Luo, our Chief Executive Officer, and Justin McAnear, Chief Financial Officer. Our President, Tod White, will join for Q&A. Earlier this afternoon, we issued a press release detailing our second quarter financial results, and we posted an accompanying presentation in the investor section of our website. Before we begin, I would like to remind you that statements we make during this call will include forward-looking statements as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties, and the company can give no assurance that they will prove to be correct. Additionally, we are not under any obligation to provide further updates on our business trends or our performance during the quarter.
To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the periodic reports that Alamar Biosciences files with the Securities and Exchange Commission, including our quarterly report on Form 10-Q, filed on May 8, 2026. I will now turn the call over to Yuling Luo, Alamar CEO.
Thank you, Kari, and thank you all for joining us this afternoon for our first earnings call as a public company. Before I begin, I want to thank our investors for their trust and support following our successful initial public offering. On behalf of the entire Alamar team, we remain committed to delivering meaningful impact while creating long-term shareholder value. I will start our call with a brief overview of Alamar and our platform, then walk through our Q2 business highlights, and close with our strategy to unlock the opportunity ahead. I will then turn it over to Justin to cover our financials and the revenue outlook for the remainder of the year. Starting on slide 3. Eight years ago, we founded Alamar with a singular mission: to power precision proteomics for the earliest possible detection of disease. That mission remains our North Star.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring